Skip to main content

Advertisement

Figure 3 | Molecular Cancer

Figure 3

From: Transglutaminase 2 as an independent prognostic marker for survival of patients with non-adenocarcinoma subtype of non-small cell lung cancer

Figure 3

Kaplan-Meier plot of DFS according to different levels of TGase 2 expression in patients in the entire NSCLC population (A) or in the non-adenocarcinoma subtype (B). For analysis of the immunohistochemical staining, the weak and intermediate TGase 2-expression groups were combined into an intermediate group. The DFS of the patients with strong TGase 2 expression (red) was significantly shorter (* and **) than that of the TGase 2-negative patients (blue) in both groups (x-axis: months after surgery; y-axis: DFS probability).

Back to article page